NCT06737042 is a Phase 2 clinical trial of GZR18 in Obesity and Overweight, sponsored by Gan and Lee Pharmaceuticals, USA.

Who is sponsoring NCT06737042?

NCT06737042 is sponsored by Gan and Lee Pharmaceuticals, USA.

What drugs are being tested in NCT06737042?

Interventions in NCT06737042: GZR18, Tirzepatide.

What condition does NCT06737042 study?

NCT06737042 studies Obesity and Overweight.

Is NCT06737042 still recruiting?

NCT06737042 is currently not yet recruiting. Last updated 4 February 2025.

Last reviewed 2025-02-04 · How we verify

NCT06737042

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants

Not yet recruiting Phase 2 Last updated 4 February 2025

What this trial tests

Phase 2 trial testing GZR18 in Obesity and Overweight in 285 participants. Not yet recruiting.

Timeline

12 February 2025

Primary endpoint
9 February 2026

22 June 2026

Quick facts

Lead sponsor	Gan and Lee Pharmaceuticals, USA
Phase	Phase 2
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	285
Start date	12 February 2025
Primary completion	9 February 2026
Estimated completion	22 June 2026
Sites	20 locations across United States

Drugs / interventions tested

GZR18 — full drug profile →
Tirzepatide (TIRZEPATIDE) — full drug profile →

Conditions studied

Obesity and Overweight — all drugs for Obesity and Overweight →

Sponsor

Gan and Lee Pharmaceuticals, USA — full company profile →

Who can join

Adults 18 to 75, any sex, with Obesity and Overweight. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase 2 study to evaluate the safety and efficacy of 24, 36, and 48 mg GZR18 (Q2W) compared with placebo and 15 mg tirzepatide (QW). The study will evaluate weight management in participants with obesity (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with weight-related comorbidities (excluding type 2 diabetes mellitus).

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

GZR18, a GLP-1 analog with once-weekly or bi-weekly dosing for body weight management: A randomized, placebo-controlled, phase 1b/2a trial.
Ji L, Gao L, Dong R, Yuan M, et al · · 2026 · PMID 41956096 · DOI 10.1016/j.xcrm.2026.102743
Efficacy and safety of bofanglutide, a GLP-1 receptor agonist, in Chinese adults with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial.
Ji L, Gao L, Tian J, Dong R, et al · · 2026 · PMID 41760612 · DOI 10.1038/s41392-026-02586-8

Verify or expand the search:

Other trials of GZR18

Trials testing the same drug.

NCT07150975 — Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese o · Phase 3 · recruiting
NCT06778967 — A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes Mellitus · Phase 3 · active not recruiting
NCT06777238 — A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Subjects With Type 2 Diabetes Melli · Phase 3 · active not recruiting
NCT06554054 — A Study of GZR18 Tablet in Chinese Healthy Subjects · Phase 1 · active not recruiting
NCT06256549 — A Study of GZR18 Injection in Chinese Patients With Type 2 Diabetes Mellitus · Phase 2 · unknown

Other recruiting trials for Obesity and Overweight

Currently open trials in the same condition.

NCT06857929 — "Improving Health and Reducing Chronic Disease Risk in Middle-Aged Adults Through Nutrition" · NA · recruiting
NCT06724172 — CHIME: Comparing Health Interventions for Maternal Equity · NA · recruiting
NCT07032545 — Metabotyping of Broccoli Microgreen in Obese Breast Cancer Survivors · NA · recruiting
NCT06768827 — New Mechanisms of Obesity · NA · recruiting
NCT06935838 — Effects of Tirzepatide on Weight Loss and Chronic Inflammation in People With HIV · Phase 2 · recruiting

Other Gan and Lee Pharmaceuticals, USA trials

Trials by the same sponsor.

NCT07242664 — Clamp Study to Estimate the Relative Potency of GZR33 Versus Insulin Degludec at Steady State · Phase 1 · recruiting
NCT07146347 — Comparison Study of Insulin GZR4 With Insulin Degludec · Phase 1 · recruiting
NCT06670209 — A Phase I Clinical Study to Evaluate the Effect of GZR18 Injection on the Pharmacokinetics of Oral Metformin Hydrochlori · Phase 1 · not yet recruiting
NCT06547502 — Pharmacokinetics and Safety Profile of a Single Dose GZR4 in Subjects with Renal Impairment · Phase 1 · completed
NCT06548906 — A Study of GZR4 Injection at Different Injection Sites · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06737042 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Gan and Lee Pharmaceuticals, USA
Last refreshed: 4 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06737042.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing